Advertisement

Topics

ARCA biopharma, Inc. Company Profile

07:20 EST 17th December 2018 | BioPortfolio

ARCA biopharma is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The Company's lead product candidate, bucindolol hydrochloride, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure. ARCA has identified common genetic variations that it believes predict individual patient response to bucindolol, giving it the potential to be the first genetically-targeted heart failure treatment. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for bucindolol. For more information please visit www.arcabiopharma.com.


News Articles [1352 Associated News Articles listed on BioPortfolio]

ARCA Biopharma Shares Soar After Positive FDA Meeting

ARCA Biopharma, located in Westminster, Colorado, announced mixed but positive outcomes from a Phase II clinical trial of its beta-blocker Gencaro for atrial fibrillation (AF) patients with heart fail...

ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Nov. 14, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted ther...

ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted thera...

ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation

Single Phase 3 trial may be sufficient for approval of atrial fibrillation indicationPhase 3 clinical trial Special Protocol Assessment submission anticipated 3Q2018Gencaro is in development as poten...

ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial

Gencaro potentially the first genetically-targeted treatment for heart failure patients at risk for atrial fibrillationPRECISION-AF, planned Phase 3 clinical trial in patients with genotype that resp...

ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions

Approximately 25% risk reduction for recurrence of AF seen in favor of Gencaro over active comparator as measured by AFB WESTMINSTER, Colo., Nov. 05, 2018 (GLOBE NEWSWIRE) --  ARCA biopharma, Inc...

Gencaro back from the brink as FDA gives Phase 3 go-ahead

Regulators have told Arca a single Phase 3 study could be sufficient to support an NDA for the heart medicine.

KBI Biopharma: How to stand out in the CMO space

KBI Biopharma is a CMO focused exclusively on biologics. Bernardo Estupinan-Gaisbauer, Vice President – Business Development at KBI Biopharma, discusses their strategy for partnering, and the challe...

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Cardene® sr [PDL BioPharma, Inc.]

CARDENE® SR

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

PubMed Articles [6 Associated PubMed Articles listed on BioPortfolio]

Rethinking the Clinically Based Thresholds of TransCelerate BioPharma for Risk-Based Monitoring.

The quality of data from clinical trials has received a great deal of attention in recent years. Of central importance is the need to protect the well-being of study participants and maintain the inte...

Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).

Dolutegravir (DTG) is a next-generation HIV integrase inhibitor (INI) with an increased genetic barrier to resistance with respect to raltegravir (RAL) or elvitegravir (EVG). Few data are available on...

The ArcAB two-component regulatory system promotes resistance to reactive oxygen species and systemic infection by Salmonella Typhimurium.

Salmonella enterica Serovar Typhimurium (S. Typhimurium) is an intracellular bacterium that overcomes host immune system barriers for successful infection. The bacterium colonizes the proximal small i...

Bicyclic bis-heteroaryl derivatives as inhibitors of the α-synuclein protein: a patent evaluation of WO2018138088A1.

Neurodegenerative diseases commonly present misfolding and aggregation of one or more proteins, including α-synuclein, β-amyloid and tau. Several research efforts have been made to develop therapeut...

ChIP-exo interrogation of Crp, DNA, and RNAP holoenzyme interactions.

Numerous in vitro studies have yielded a refined picture of the structural and molecular associations between Cyclic-AMP receptor protein (Crp), the DNA motif, and RNA polymerase (RNAP) holoenzyme. In...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and ...

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Companies [148 Associated Companies listed on BioPortfolio]

ARCA biopharma, Inc.

ARCA biopharma is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The Company's lead product candidate, bucindolol hydro...

SAFE-BioPharma Association

SAFE-BioPharma Association (www.safe-biopharma.org) is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the ...

Kedrion Biopharma, Inc.

Kedrion Biopharma is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and pre...

Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-b...

SAFE-BioPharma Association, LLC

As part of the National Health Information Sharing and Analysis Center (NH-ISAC), SAFE-BioPharma Association, LLC [www.safe-biopharma.org] provides global, high-assurance identity...

More Information about "ARCA biopharma, Inc." on BioPortfolio

We have published hundreds of ARCA biopharma, Inc. news stories on BioPortfolio along with dozens of ARCA biopharma, Inc. Clinical Trials and PubMed Articles about ARCA biopharma, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ARCA biopharma, Inc. Companies in our database. You can also find out about relevant ARCA biopharma, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...


Corporate Database Quicklinks



Searches Linking to this Company Record